US4701408A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody to activated macrophages
Assignee: SMITHLINE BECKMAN Corp ONE FRANKLIN PLAZA PHILADELPHIA PA 19103 A CORP OF PA
•
Filing: 1984-01-30
•
Granted: 1987-10-20
•
Expires: 2004-01-30
Abstract
Abstract A monoclonal antibody which is preferentially reactive with activated macrophages and a hybridoma which produces the antibody.
Inventors
- 👤 Thomas P. Koestler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 15:48
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
61 words
A monoclonal antibody of class IgG produced and secreted by a hybridoma formed by fusion of cells from a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophages, the antibody being reactive with thioglycollate-, proteose-peptone-, Concanavalin A-, and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF-activated macrophages than with thioglycollate-elicited macrophages.
Claim 2
Dependent Claim
61 words
A monoclonal antibody of class IgG produced and secreted by a hybridoma formed by fusion of cells from a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophages, the antibody being reactive with thioglycollate-, proteose-peptone-, Concanavalin A-, and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF-activated macrophages than with thioglycollate-elicited macrophages.
Claim 3
Dependent Claim
36 words
The monoclonal antibody of claim 1 which has one heavy and one light chain, does not adsorb to S. aureus (Cowan 1) protein, is of the IgG2a subclass, and reacts with macrophages elicited with Corynebacterium parvum.
Claim 4
Dependent Claim
22 words
The monoclonal antibody of claim 2 produced and secreted by the hybridoma wherein the spleen cells are previously immunized against mouse macrophages.
Claim 5
Dependent Claim
32 words
The monoclonal antibody of claim 3 produced and secreted by the hybridoma wherein the myeloma cell line is a murine myeloma cell line and the spleen cells are from a murine animal.
Claim 6
Dependent Claim
19 words
The monoclonal antibody of claim 4 produced and secreted by the hybridoma wherein the myeloma cell line is SP2/O-Ag14.
Claim 7
Dependent Claim
13 words
The monoclonal antibody of claim 5 wherein the hybridoma is 158.2 (ATCC HB-8466).
Claim 8
Dependent Claim
15 words
The monoclonal antibody of claim 5 which is MA158.2 (monoclonal antibody from ATCC HB 8466).
Claim 9
Dependent Claim
62 words
A hybridoma comprising a cell formed by fusion of a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophages which hybridoma produces and secretes a monoclonal antibody of class IgG which reacts with thioglycollate-, proteose-peptone-, Concanavalin A- and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF activated macrophages than with thioglycollate-elicited macrophages.
Claim 10
Dependent Claim
62 words
A hybridoma comprising a cell formed by fusion of a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophages which hybridoma produces and secretes a monoclonal antibody of class IgG which reacts with thioglycollate-, proteose-peptone-, Concanavalin A- and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF activated macrophages than with thioglycollate-elicited macrophages.
Claim 11
Dependent Claim
41 words
The hybridoma of claim 8 which produces and secretes an antibody which has one heavy and one light chain, does not adsorb to S. aureus (Cowan 1) protein, is of the IgG2a subclass, and reacts with macrophages elicited with Corynebacterium parvum.
Claim 12
Dependent Claim
25 words
The hybridoma of claim 9 wherein the myeloma cell line is a murine myeloma cell line and the spleen cells are from a murine animal.
Claim 13
Dependent Claim
12 words
The hybridoma of claim 10 wherein the myeloma cell line is SP2/O-Ag14.
Claim 14
Dependent Claim
10 words
The hybridoma of claim 11 which is 158.2 (ATCC HB-8466).
Claim 15
Independent Claim
140 words
A method of screening a solution or mixture for macrophage activating activity which comprises treating a macrophage culture with the solution or mixture for a time and under conditions sufficient to permit activation to occur; contacting the treated culture with an antibody of class IgG produced and secreted by a hybridoma formed by fusion of cells from a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophage, the antibody being reactive with thioglycollate-, proteose-peptone-, Conconavalin A-, and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF-activated macrophages that with thioglycollate-elicited macrophages, for a time and under conditions sufficient to permit binding of the antibody to activated cells; and assaying for enhanced binding of the antibody to the cells, said enhanced binding being an indication of the presence of macrophage activating activity.
Claim 16
Independent Claim
140 words
A method of screening a solution or mixture for macrophage activating activity which comprises treating a macrophage culture with the solution or mixture for a time and under conditions sufficient to permit activation to occur; contacting the treated culture with an antibody of class IgG produced and secreted by a hybridoma formed by fusion of cells from a myeloma cell line and spleen cells from a mammal previously immunized with MAF-activated macrophage, the antibody being reactive with thioglycollate-, proteose-peptone-, Conconavalin A-, and LPS-elicited macrophages, but which is at least about three-fold more reactive with MAF-activated macrophages that with thioglycollate-elicited macrophages, for a time and under conditions sufficient to permit binding of the antibody to activated cells; and assaying for enhanced binding of the antibody to the cells, said enhanced binding being an indication of the presence of macrophage activating activity.
Claim 17
Dependent Claim
37 words
The method of claim 13 wherein the antibody has one heavy and one light chain, does not adsorb to S. aureus (Cowan 1) protein, is of the IgG2a subclass, and reacts with macrophages elicited with Corynebacterium parvum.
Claim 18
Dependent Claim
15 words
The method of claim 14 wherein the spleen cells are previously immunized with mouse macrophages.
Claim 19
Dependent Claim
25 words
The method of claim 15 wherein the myeloma cell line is a murine myeloma cell line and the spleen cells are from a murine animal.
Claim 20
Dependent Claim
14 words
The method of claim 16 wherein the macrophage culture is derived from a mouse.
Claim 21
Dependent Claim
12 words
The method of claim 16 wherein the myeloma cell line is SP2/0-Ag14.
Claim 22
Dependent Claim
15 words
The method of claim 18 wherein the antibody is MA158.2 (monoclonal antibody from ATCC HB-8466).
Claim 23
Dependent Claim
14 words
The method of claim 18 wherein the macrophage culture is derived from a mouse.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-19 | 1991-04-20 | 1991-10-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-19 | 1995-04-20 | 1995-10-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-19 | 1999-04-20 | 1999-10-20 | $7700.00 | Window Closed / Lapsed |